Asco 2021 – Alkermes’s disappointment hones melanoma niche focus
Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.
Abingworth taps biopharma’s appetite for risk-sharing
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
AACR 2021 – still awaiting validation, Sanofi keeps on buying
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Merck gets on the Treg train with Pandion buy
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Esmo 2020 – can Alkermes succeed where Nektar failed?
Early signs suggest that Alkermes might have found a therapeutic window with its IL-2-targeting agent, ALKS 4230.
Bristol bets on cytokines again
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
